Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

PHASE4CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

May 28, 2018

Primary Completion Date

May 5, 2020

Study Completion Date

February 21, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Mavenclad®

Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.

Trial Locations (54)

133

IRCSS Neuromed Istituto Neurologico Mediterraneo, Roma

2170

Liverpool Hospital, Sydney

3181

The Alfred Hospital, Prahran

5020

Paracelsus Medical University Salzburg, Salzburg

6009

Perron Institute - Neurology, Nedlands

6701

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo, Szeged

9020

Klagenfurt1, Klagenfurt

15006

Fakultni nemocnice v Motole, Prague

20521

Turku University Hospital, Turku

28035

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

28046

Hospital Clinico San Carlos, Madrid

30004

CHU Montpellier-Nîmes - Hôpital Caremeau, Nîmes

30029

CHU Nîmes, Nîmes

30625

Medizinische Hochschule Hannover, Hanover

31096

Rambam MC, Haifa

33520

FinnMedi Oy vastaanotto - Finn-Medi 3, Tampere

35033

CHU de Pontchaillou, Rennes

41009

Hospital Vithas NISA Sevilla, Seville

46009

Hospital La Fe, Valencia

48149

Universitätsklinikum Münster, Münster

48903

Hospital de Cruces, Baracaldo Vizcaya

52621

The Chaim Sheba Medical Center, Tel Litwinsky

53100

Universita di SIENA, Siena

53105

Universitätsklinikum Bonn, Bonn

56501

FN Hradec Kralove, Choceň

59037

CHRU de Lille, Lille

65691

Fakultni nemocnice u sv. Anny v Brne, Brno

67091

Hôpital Civil, Strasbourg

78303

CHU de Poissy, Poissy

78306

Barzilai Medical Center, Ashkelon

80131

Seconda Univesità degli Studi di Napoli, AOU, Napoli

2310-2305

John Hunter Hospital, Hunter Region Mail Centre

V6T 1Z3

MS Clinical Trials Group, Vancouver

N6A 5A5

UB - State University of New York, London

T6G 2G3

University of Alberta, Edmonton

H3A 2B4

Montreal Neurological Hospital, Montreal

630 00

Fakultni nemocnice Brno, Brno-Bohunice

532 03

Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice, Pardubice

Unknown

Helsinki University Central Hospital, Helsinki

Neuro Centrum Science GmbH, Erbach im Odenwald

Universitätsklinikum Essen, Essen

Neurologische Praxis Eppendorf, Hamburg

Policlinico Universitario SS Annunziata, Chieti

06002

CHU Nice - Hôpital Pasteur, Nice

01307

Universitätsklinikum Carl Gustav Carus, Dresden

04103

Universitätsklinikum Leipzig, Leipzig

20-954

Indywidualna Praktyka Lekarska Prof. Konrad Rejdak, Lublin

40-662

Samodzielny Publiczny Szpital Kliniczny nr 7 SUM, Katowice

41-800

Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach, Zabrze

416 85

Sahlgrenska Universitetssjukhus, Gothenburg

171 76

Akademiskt Specialist Centrum - Centrum för Neurologi, plan 5, Stockholm

CF14 4XN

University Hospital of Wales, Cardiff

B15 2TH

Queen Elizabeth Hospital, Birmingham

SI0 2JF

Sheffield Teaching Hospitals Sheffield, Sheffield

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03364036 - Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) | Biotech Hunter | Biotech Hunter